FBInvestor
Stocks / Merrimack Pharmaceuticals In
Institutional Ownership

Merrimack Pharmaceuticals In

CUSIP 590328209COMMACKEURQ1 2026

13D / 13G Filings
22
Schedule 13D/13G on record
Beneficial Filers
10
Distinct reporting persons
Largest Stake
15.5%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

22 filings · latest Mar 7, 2024

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Mar 7, 2024Blackrock Inc.13G/A5.0%715.3KSEC
2Feb 22, 2024Adar1 Partners, LP13G6.3%902.4KSEC
3Feb 14, 202422nw Fund, LP13G/ASEC
4Jan 31, 2024Blackrock Inc.13G5.2%743.6KSEC
5Jan 25, 2024Newtyn Management, LLC13D/A13.1%1.87MSEC
6Dec 13, 2023Western Standard LLC13D/A15.5%2.22MSEC
7Aug 14, 2023Western Standard LLC13D/A13.9%1.99MSEC
8Feb 14, 2023Point72 Asset Management, L.P.13G/ASEC
9Feb 13, 202322nw Fund, LP13G/A7.6%1.02MSEC
10Aug 4, 2022Point72 Asset Management, L.P.13G6.7%900.5KSEC

12 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Merrimack Pharmaceuticals In.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →